comparemela.com

Latest Breaking News On - Bharat biotechs covaxin - Page 7 : comparemela.com

69% Indians Still Hesitant To Take COVID-19 Vaccine, Reveals LocalCircles Survey

69% Indians still hesitant to take COVID-19 vaccine, reveals LocalCircles survey Only 26 percent respondents (out of a total of 8,723) have said that they would want to get vaccinated as soon as the COVID-19 vaccination drive begins, regardless of whether it is through a government channel or private. January 06, 2021 / 03:31 PM IST The DCGI has approved Oxford-AstraZeneca s Covishield and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in India. At a time when India is barely a week away from rolling out its coronavirus vaccination drive, a survey has revealed that 69 percent Indians are hesitant about getting vaccine shots.A survey conducted by ‘LocalCircles’ in January has concluded that most Indians do not wish to rush the process. They are hesitant about getting the COVID-19 vaccine shots.

India
Bharat
Oxford-astrazeneca-covishield
Rajesh-bhushan
Health-ministry
Serum-institute-of-india
Bharat-biotech
Serum-institute
Health-ministry-secretary-rajesh-bhushan
Local-circles
Bharat-biotechs-covaxin
Bharat-biotech-coronavirus-vaccine

Bharat Biotech Oxford Covaxin Covishield Serum Institute DCGI final approval coronavirus vaccine emergency use

URL copied Covishield, Covaxin get govt s nod Drug Controller General of India (DCGI) on Sunday approved Serum Institute of India s Covishield vaccine and Bharat Biotech s Covaxin for emergency use against coronavirus. The development, eleven months after the first case of deadly coronavirus was detected in India, has paved the way for their roll-out and administration to millions. The vaccine will be first offered to one crore healthcare workers, along with two crore frontline and essential workers and 27 crores elderly, mostly above the age of 50 years with co-morbidities. The expert panel has recommended granting permission for restricted emergency use of Covaxin in public interest as an abundant precaution, in clinical trial mode, especially in the context of infection by mutant strains.

India
Syria
United-kingdom
Argentina
Pune
Maharashtra
Syrian
Bharat
Oxford-astrazeneca-covishield
Astrazeneca-oxford-university
Serum-institute-of-india-covishield
National-institute-of-virology

Coronavirus vaccine Oxford AstraZeneca Serum Institute PM Modi on DCGI approval Covishield Covaxin for emergency use

URL copied Image Source : PTI Would make every Indian proud: PM Modi on DCGI final approval to Covishield, Covaxin for emergency use The Drug Controller General of India (DCGI) on Sunday approved the emergency use of both Oxford-AstraZeneca Covishield vaccine and Bharat Biotech’s Covaxin vaccine for immunisation against Covid-19 in India. Prime Minister Narendra Modi took to Twitter to appreciate India s vaccine against Coronavirus and said it would make every Indian proud. We reiterate our gratitude to doctors, medical staff, scientists, police personnel, sanitation workers and all Corona warriors for the outstanding work done, that too in adverse circumstances. We will remain eternally grateful to them for saving many lives, PM Modi Tweeted.

India
Oxford-astrazeneca-covishield
Narendra-modi
Aatmanirbhar-bharat
Twitter
Image-source
Drug-controller-general
Bharat-biotech
Prime-minister-narendra-modi
Cadila-healthcare
Oxford-astrazeneca
Coronavirus-vaccine

Coronavirus vaccine roll out: Crucial Panel Meet at 12 pm on approval for Oxford-AstraZeneca

Coronavirus vaccine roll out: Crucial Panel Meet at 12 pm on approval for Oxford-AstraZeneca Reports suggest that an expert panel will meet to take up the application for emergency use of the three vaccines BusinessToday.In | January 1, 2021 | Updated 11:50 IST A crucial vaccine panel meeting at 12 pm on Friday, January 1, will most likely take the decision on the approval for public use of the COVID-19 vaccines in India. The Central Drugs Standard Control Organisation (CDSCO) had met thrice before over the approval of vaccines. Reports suggest that an expert panel will meet to take up the application for emergency use of the three vaccines developed by the Serum Institute and AstraZeneca/Oxford s Covishield vaccine, Bharat Biotech s Covaxin and US based Pfizer s coronavirus vaccine.

China
Dawai
Fujian
India
Rajkot
Gujarat
Narendra-modi
Astrazeneca-oxford-covishield
Pfizer
Astrazeneca-oxford-university
Serum-institute
Serum-institute-of-india

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.